Hidden Cybersecurity Roadblocks That Can Slow An FDA Medical Device Submission

Cybersecurity has become part of the regulatory work behind many connected medical devices. Manufacturers may spend months developing security controls yet still encounter submission problems because the documentation does not clearly demonstrate how those controls address device risks.

Cybersecurity May Enter the Process Too Late

One common problem begins long before a submission reaches the FDA. Cybersecurity can be treated as a final verification exercise rather than part of product development. That approach creates problems when engineers later need to explain why particular security controls were selected.

FDA guidance emphasizes incorporating cybersecurity throughout the total product life cycle. That makes early coordination between engineering, security, quality, regulatory, and software teams important. Waiting until submission preparation can expose missing evidence that is difficult to recreate.

Threat Modeling Needs to Match the Actual Device

Generic cybersecurity documentation may describe common threats without showing how an attacker could affect the specific device. Effective threat modeling considers the device architecture, interfaces, data flows, trust boundaries, external connections, and potential attack paths.

A disconnected set of security documents can create another problem. Threat models, risk assessments, architecture diagrams, and testing results should describe the same system. If one document shows an interface that another document ignores, reviewers may need additional clarification.

The Software Bill of Materials Can Reveal Gaps

Connected devices commonly depend on third-party and open-source software. Those components create dependencies that manufacturers still need to track.

For cyber devices subject to Section 524B of the Federal Food, Drug, and Cosmetic Act, manufacturers must provide a software bill of materials covering commercial, open-source, and off-the-shelf software components. The FDA also expects manufacturers to address how vulnerabilities will be monitored and managed after release.

An incomplete component inventory can therefore create problems beyond the SBOM itself. If the manufacturer does not know exactly which software is present, assessing vulnerabilities and explaining future update processes becomes much harder.

Premarket and Postmarket Plans Must Connect

Cybersecurity work does not end when a device receives authorization. FDA requirements for cyber devices include plans and procedures for monitoring, identifying, and addressing postmarket vulnerabilities. This means submission documentation should explain how the manufacturer will respond when vulnerabilities emerge.

The cybersecurity documentation required can also depend on the regulatory pathway and device. Teams comparing the types of FDA submissions for medical devices should determine early which regulatory requirements and current FDA guidance apply rather than assuming a previous submission provides a complete template.

Testing Evidence Needs Context

A penetration test report alone does not explain the entire security posture of a device. Reviewers need enough context to see what was tested, what was found, how findings were addressed, and how testing relates to identified risks. This is where traceability becomes valuable. Security requirements should connect logically with threats, controls, and residual risk decisions.

Many cybersecurity roadblocks in FDA submissions are documentation and process problems rather than last-minute technical failures. Early threat modeling, accurate software inventories, coordinated postmarket planning, and traceable evidence give regulatory teams a clearer story to present. Look over the infographic below to learn more.